Study summary · research use only
Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human study analyzed patients with clinically nonfunctioning pituitary adenoma (NFPA) who underwent transsphenoidal surgery, evaluating postoperative growth hormone (GH) secretion in response to GH-releasing peptide-2 (GHRP2) infusion and factors affecting GH dynamics. Of 119 patients analyzed, 94 (79.0%) had peak GH levels less than 9.0 ng/mL and were diagnosed with severe GH deficiency (sGHD) immediately after surgery; of those, 27 (28.7%) recovered from sGHD within 1-2 years after surgery. Univariate analyses found sGHD recovery was more frequent in younger patients, those with only a single primary surgery, no anterior hormone deficiency besides GH, and cystic adenoma or normal IGF1 standard deviation score levels immediately after surgery; multivariate analyses found younger age and absence of hormone replacement therapy predicted sGHD recovery within 1-2 years.
Abstract
Growth hormone deficiency (GHD) is an endocrine disorder characterized by insufficient production of growth hormone (GH). Non-functioning pituitary adenoma (NFPA) is one of common causes of GHD. Although most patients with NFPA have transsphenoidal surgery, the time-dependent changes in GH after operation have yet to be investigated. In this study, we analyzed patients with NFPAs that underwent transsphenoidal surgery. Postoperatively, GH secretion was evaluated in response to GH-releasing peptide-2 (GHRP2) infusion. We also investigated how several factors affected GH dynamics. Of 119 patients analyzed, 94 (79.0%) had peak GH levels less than 9.0 ng/mL and were diagnosed with severe GHD (sGHD) immediately after surgery. Of those patients, 27 (28.7%) recovered from sGHD within 1-2 years after surgery. Univariate analyses confirmed that sGHD recovery improved significantly in patients that were younger, had only undergone a single primary surgery, had not had anterior hormone deficiency except GH, and had cystic adenoma or normal insulin-like growth factor-1 (IGF1) standard deviation score (SD-S) levels immediately after surgery. Multivariate analyses confirmed that younger age and absence of hormone replacement therapy significantly predicted sGHD recovery within 1-2 years after surgery. Taken together, our results indicated that postoperative sGHD should be assessed by GHRP2 infusion, regardless of IGF1 SD-S levels. Furthermore, recovery from sGHD occurs more frequently at 1-2 years after surgery especially in younger patients and/or those with GH deficiency alone. These patients, therefore, should be reassessed for GHD by appropriate tests including GHRP2 test at 1-2 years after surgery.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.